 |
|
|
|
|
|
Treatment |
|
Location |
|
Last Updated |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Chicago, IL USA |
|
05/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Durham, NC USA |
|
05/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Charlottesville, VA USA |
|
05/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Cleveland, OH USA |
|
05/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Cleveland, OH USA |
|
05/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Hackensack, NJ USA |
|
05/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Chicago, IL USA |
|
05/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Boston, MA |
|
05/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
New Haven, CT USA |
|
05/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Buffalo, NY USA |
|
05/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Salt Lake City, UT USA |
|
05/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Evanston, IL USA |
|
05/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Palo Alto, CA USA |
|
05/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
New York, NY USA |
|
05/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Philadelphia, PA USA |
|
05/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Houston, TX USA |
|
05/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Seattle, WA USA |
|
05/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
New York, NY USA |
|
05/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Jacksonville, FL USA |
|
05/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
San Francisco, CA USA |
|
05/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Saginaw, MI USA |
|
05/09/2008 |
|
|
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
Gainsville, FL USA |
|
05/09/2008 |
|
|
|
Details |
|
A Phase II/III Randomized Study of CDX-110 With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme |
|
San Antonio, TX USA |
|
05/09/2008 |
|
|
|
|
|
Details |
|
A Phase II Trial of Thalidomide in combination with Temozolomide or CPT-11 in patients with recurrent anaplastic gliomas or glioblastoma multiforme
|
|
Houston, TX USA |
|
04/16/2008 |
|
|
|
Details |
|
A Phase II Study of Rituximab and Temozolomide in Recurrent Primary CNS Lymphoma
|
|
Houston, TX USA |
|
04/16/2008 |
|
|
|
|
|
Details |
|
Phase I/II Study of OSI-774 (Erlotinib) and CCI-779 (Temsirolimus) in Patients with Recurrent Malignant Glioma
|
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
Details |
|
A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma
|
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase 2, 2-part, multicenter, open-label study to evaluate the safety, tolerability, and efficacy of CT-322 (Angiocept™) monotherapy and combination therapy with irinotecan in patients with recurrent glioblastoma multiforme
|
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Durham, NC USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Los Angeles, CA USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
New York, NY USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
San Antonio, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Bethesda, MD USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Madison, WI USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Pittsburgh, PA USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase I/II Studies of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib), R115777 (Tipifarnib) or CCI-779 (Temsirolimus) in Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma |
|
Boston, MA USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
Durham, NC USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
Los Angeles, CA USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
San Francisco, CA USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
Madison, WI USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
New York, NY USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
San Antonio, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
Bethesda, MD USA |
|
04/15/2008 |
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
Pittsburgh, PA USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
Phase II Single Arm Trial of VEGF Trap in Patients With Recurrent Temozolomide-Resistant Malignant Gliomas |
|
Boston, MA USA |
|
04/15/2008 |
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
New York, NY USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Durham, NC USA |
|
04/15/2008 |
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Houston, TX USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Los Angeles, CA USA |
|
04/15/2008 |
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Bethesda, MD USA |
|
04/15/2008 |
|
|
|
|
|
Details |
|
A Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Temozolomide in Patients with Malignant Gliomas |
|
Boston, MA |
|
04/15/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Houston, TX USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Phoenix, AZ USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Springfield, MO USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Greenville, SC USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Spartanburg, SC USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Galveston, TX USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Kalamazoo, MI USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
San Antonio, TX USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Akron, OH USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Kingsport, TN USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Newark, DE USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Jacksonville, FL USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Mobile, AL USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Sacramento, CA USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Columbus, GA USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Harvey, IL USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Saint Louis Park, MN USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Marlton, NJ USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Akron, OH USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Canton, OH USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Wooster, OH USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Lubbock, TX USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Murray, UT USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Salt Lake City, UT USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Provo, UT USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Burlington, VT USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Yakima, WA USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Milwaukee, WI USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
Hershey, PA USA |
|
04/11/2008 |
|
|
|
|
|
Details |
|
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme |
|
New York, NY USA |
|
04/11/2008 |
|
|
|
Details |
|
Phase I/II Study of GP96 Heat Shock Protein-Peptide Complex Vaccine in Patients With Recurrent or Progressive High-Grade Glioma |
|
San Francisco, CA USA |
|
03/02/2008 |
|
|
|
|
|
Details |
|
A phase I/II Evaluation of Vaccination with Type-1 Dendritic Cells Pulsed With Multiple Peptides In the Treatment of HLA-A2 Positive Patients With Recurrent Malignant Gliomas |
|
Pittsburgh, PA USA |
|
03/02/2008 |
|
|
|
Details |
|
Phase I Study of Immunization With Autologous Tumor Lysate-Pulsed Dendritic Cells in Patients With Malignant Gliomas (Vaccine Therapy in Treating Patients With Malignant Glioma) |
|
Los Angeles, CA USA |
|
03/02/2008 |
|
|
|
|
|
Details |
|
Chemotherapy, Radiation Therapy, and Vaccine Therapy With or Without Daclizumab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery |
|
Durham, NC USA |
|
03/02/2008 |
|
|
|
Details |
|
Phase ll Trial of Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Patients With Atypical or Malignant, Primary or Metastatic Brain Tumors of the Central Nervous System |
|
Los Angeles, CA USA |
|
03/02/2008 |
|
|
|
|
|
Details |
|
A Phase l Trial of Tumor Associated Antigen Pulsed Dendritic Cell Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma |
|
Los Angeles, CA USA |
|
03/02/2008 |
|
|
|
Details |
|
Phase I Dose Escalation Study of Autologous Tumor Lysate-Pulsed Dendritic Cell Immunotherapy for Malignant Gliomas in Pediatric Patients |
|
Los Angeles, CA USA |
|
03/02/2008 |
|
|
|
|
|
Details |
|
Phase I Study of Glioma-Associated Antigen (GAA) Peptide-Pulsed Dendritic Cell Vaccination in Malignant Glioma Patients |
|
Los Angeles, CA USA |
|
03/02/2008 |
|
|
|
Details |
|
A Phase l Trial of Surgical Resection With Gliadel Wafer Placement Followed by Vaccination With Dendritic Cells Pulsed With Tumor Lysate for Patients With Malignant Glioma
|
|
Los Angeles, CA USA |
|
03/02/2008 |
|
|
|
|
|
Details |
|
Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-Specific T-Cell Adoptive Transfer [ERaDICATe] |
|
Durham, NC USA |
|
03/02/2008 |
|
|
|
Details |
|
Phase I/II trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine For Patients With Recurrent High Grade Glioma |
|
San Francisco, CA USA |
|
10/03/2007 |
|
|
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
New York, NY USA |
|
08/26/2007 |
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
Cincinnati,, OH USA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
Columbus, OH USA |
|
08/26/2007 |
|
|
|
Details |
|
A Pharmacokinetic and Phase 2 Study of Sunitinib Malate in Recurrent Malignant Gliomas |
|
Toronto, Ontario, CANADA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
A Phase I/II Study of ATN-161 and Carboplatin in Adult Patients With Recurrent Intracranial Malignant Glioma |
|
Bethesda, MD USA |
|
08/26/2007 |
|
|
|
Details |
|
Dynamic Contrast-Enhanced Magnetic Resonance Imaging With Bevacizumab (Avastin) in Combination With Irinotecan (CPT-11) for Malignant Gliomas |
|
Durham, NC USA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
Phase I Dose Escalation of Gleevec in Combination With PTK787/ZK 222584 (PTK/ZK) Plus Hydroxyurea |
|
Durham, NC USA |
|
08/26/2007 |
|
|
|
Details |
|
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme |
|
Winston-Salem, NC USA |
|
08/26/2007 |
|
|
|
|
|
Details |
|
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme |
|
Baltimore, MD USA |
|
08/26/2007 |
|
|
|
Details |
|
A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients With Progression or Recurrent Glioblastoma Multiforme |
|
Detroit, MI USA |
|
08/26/2007 |
|
|
|
|
